Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYLM's Equity-to-Asset is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 0.54 * Ranked among companies with meaningful Equity-to-Asset only.
Central Asia Lumeichun Biotechnology (OTCPK:ZYLM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Central Asia Lumeichun Biotechnology Equity-to-Asset Related Terms
Central Asia Lumeichun Biotechnology Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology Equity-to-Asset Chart
ZYLM vs RHE, DVCR, FVE: Equity-to-Asset Comparison
For the Farm Products subindustry, Central Asia Lumeichun Biotechnology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Asia Lumeichun Biotechnology Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Central Asia Lumeichun Biotechnology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Central Asia Lumeichun Biotechnology's Equity-to-Asset falls into.
Central Asia Lumeichun Biotechnology Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology (ZYLM) has a Equity-to-Asset of 0.26 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's Equity-to-Asset too high?
Central Asia Lumeichun Biotechnology's current Equity-to-Asset is 0.26. The Consumer Packaged Goods industry median Equity-to-Asset is 0.54. Central Asia Lumeichun Biotechnology's value of 0.26 is 51.9% below this industry median.
How does Central Asia Lumeichun Biotechnology's Equity-to-Asset compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's Equity-to-Asset of 0.26 can be compared against companies in the Consumer Packaged Goods industry. The industry median Equity-to-Asset is 0.54. Central Asia Lumeichun Biotechnology's value of 0.26 is 51.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.54, based on 2,016 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Asia Lumeichun Biotechnology's current Equity-to-Asset of 0.26 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Central Asia Lumeichun Biotechnology and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Asia Lumeichun Biotechnology's current Equity-to-Asset is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current Equity-to-Asset of 0.26. The current Equity-to-Asset is 0.26 and 51.9% below the Consumer Packaged Goods industry median of 0.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current Equity-to-Asset is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYLM has been successfully added to your 
